10-K: Encompass Health's Strong 2025 Growth & Strategic Expansion

Encompass Health Corporation reports robust 2025 financial performance driven by volume growth and strategic hospital expansions, alongside ongoing regulatory challenges and a positive long-term outlook.

Summary

• Net operating revenues increased 10.5% to $5,935.2 million in 2025 from $5,373.2 million in 2024.
• Net income attributable to Encompass Health rose 24.2% to $566.2 million in 2025 from $455.7 million in 2024.
• Discharges increased by 6.0% to 263,299 in 2025, with same-store discharges up 3.4%.
• Net patient revenue per discharge grew 3.9% to $21,862 in 2025.
• Opened 7 new inpatient rehabilitation hospitals and added 177 beds to existing hospitals in 2025.
• The quarterly cash dividend increased to $0.19 per share in July 2025.
• Repurchased 1.5 million shares of common stock for $158.0 million in 2025.
• Adjusted EBITDA increased 14.9% to $1,267.9 million in 2025 from $1,103.7 million in 2024.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this filing positively due to strong financial growth, strategic expansion, and effective capital management, despite ongoing regulatory and labor challenges. The long-term demographic trends also support continued demand for services.

Positives

• Net operating revenues increased 10.5% to $5,935.2 million in 2025, driven by volume growth and increased pricing.
• Net income attributable to Encompass Health increased 24.2% to $566.2 million in 2025.
• Discharges grew 6.0% to 263,299 in 2025, including a 3.4% increase in same-store discharges.
• Net patient revenue per discharge increased 3.9% to $21,862 in 2025, reflecting favorable reimbursement rates and decreased revenue reserves for bad debt.
• The company successfully expanded its capacity by opening 7 new inpatient rehabilitation hospitals and adding 177 beds to existing hospitals in 2025.
• The quarterly cash dividend was increased to $0.19 per share in July 2025, demonstrating commitment to shareholder returns.
• Repurchased 1.5 million shares of common stock for $158.0 million in 2025 under an active repurchase authorization.
• Adjusted EBITDA increased 14.9% to $1,267.9 million in 2025, indicating strong operational performance.
• Occupancy percentage improved to 75.9% in 2025 from 74.6% in 2024, showing better utilization of facilities.
• Long-term demand for services is supported by favorable demographic trends, with the population aged 75 and over expected to grow approximately 4% per year through 2030.
• The company maintains a strong, well-capitalized balance sheet with no significant debt maturities until 2028 and $824 million available under its revolving credit facility.
• Employee engagement scores were 84.2% favorable in 2025, exceeding the healthcare benchmark in all 10 categories by an average of 12.1%.
• Tax provisions from the One Big Beautiful Bill Act (OBBBA) resulted in approximately $22 million in cash tax savings in 2025 due to extended bonus depreciation and immediate expensing of R&D costs.

Negatives

• Outpatient visits decreased by 24.4% in 2025 compared to 2024.
• General and administrative expenses increased 12.9% in 2025, primarily due to higher incentive compensation and costs associated with the transition to a new ERP system (Oracle Fusion).
• Salaries and benefits increased 7.4% in 2025, indicating ongoing labor cost pressures and increased FTEs.
• None of the company's hospitals in Alabama achieved the opt-out claim validation rate for the second or third cycles of the Review Choice Demonstration (RCD), suggesting ongoing challenges with Medicare claim reviews.
• MedPAC approved recommending a 7% reduction in the base payment rate under the IRF-PPS to Congress at its January 2026 meeting.
• While Medicaid supplemental payments increased by $39.0 million, provider tax expenses also increased by $33.4 million, partially offsetting the benefit.
• The closure of a joint venture inpatient rehabilitation hospital in Eau Claire, Wisconsin, in February 2024, resulted in a one-time impairment charge of $10.4 million (net impact of $1.8 million to Encompass Health).

Risks

• Reductions or delays in, or suspension of, reimbursement for services by governmental or private payors, including inability to obtain and retain favorable arrangements with third-party payors, could decrease revenues and adversely affect operating results.
• Restrictive interpretations of regulations governing reimbursable claims by Medicare could decrease revenues and adversely affect operating results.
• Reimbursement claims are subject to various audits (e.g., RACs, UPICs, TPE) that may lead to assertions of overpayment or improper claims, requiring additional costs to defend and potentially refunds.
• Substantive and procedural deficiencies in the administrative appeals process for denied Medicare reimbursement claims could delay or reduce reimbursement.
• Efforts to reduce payments to healthcare providers by third-party payors and conveners, including restrictive coverage determinations by Medicare Advantage plans, could adversely affect revenues or profitability.
• Changes in payor mix (e.g., shift to lower-reimbursement Medicare Advantage or Medicaid) or patient acuity could reduce revenues or profitability.
• Changes in healthcare industry rules and regulations at federal, state, or local levels, including national healthcare reform and deficit reduction efforts, could decrease revenues and increase compliance costs.
• Non-compliance with extensive and frequently changing laws and regulations (patient care, coding, billing, data privacy, anti-kickback, Stark Law) could result in penalties, significant defense costs, or operational changes.
• Inability to maintain proper local, state, and federal licensing, including compliance with Medicare conditions of participation and provider enrollment requirements, could decrease revenues.
• Incidents affecting the proper operation, availability, or security of information systems (including cyberattacks, data breaches) could cause substantial losses, disrupt operations, and lead to litigation or regulatory action.
• Adverse outcomes of various lawsuits, claims, and legal or regulatory proceedings, including undisclosed qui tam suits, could adversely affect financial results or operations.
• Inability to successfully complete and integrate de novo developments, acquisitions, investments, and joint ventures consistent with growth strategy could adversely affect financial results.
• Inability to attract and retain nurses, therapists, and other healthcare professionals in a highly competitive environment with staffing shortages and potential union activity could increase staffing costs and adversely affect results.
• Competitive pressures in the healthcare industry, including from large acute-care hospitals and other post-acute providers, could adversely affect revenues or financial results.
• Inability to provide a consistently high quality of care, as represented in metrics published by Medicare, could decrease revenues.
• Inability to maintain or develop relationships with patient referral sources, including joint venture hospitals, could decrease revenues.
• Operational or financial challenges experienced by acute-care hospitals participating in joint ventures could affect the company's joint venture inpatient rehabilitation hospitals.
• A pandemic, epidemic, or other widespread infectious disease outbreak or public health crisis could decrease patient volumes, pricing, and revenues, lead to staffing/supply shortages, and interrupt operations.
• Regional or global socio-political, weather, or other catastrophic events could severely disrupt business, particularly in areas with hospital concentrations (e.g., Texas, Florida).
• Regulatory and other efforts to promote a transition to a lower-carbon economy may result in significant operational and financial challenges and increased costs.
• General conditions in the economy and capital markets (e.g., rising interest rates, governmental impasses) could adversely affect financial results, access to capital, and interest expense.
• High debt levels and associated restrictive covenants could limit the ability to borrow, make the company vulnerable to adverse conditions, and restrict business plan execution.
• The price of common stock could adversely affect willingness and ability to repurchase shares, and the company may be unable or unwilling to continue to declare and pay dividends.

Future Outlook

Encompass Health is optimistic about its intermediate and long-term prospects, driven by an aging population and increasing demand for its services. The company plans to continue expanding its network of inpatient rehabilitation hospitals, adding capacity to existing facilities, and strengthening relationships with healthcare systems and payors. It aims to adapt to regulatory changes, maintain a flexible capital structure, and leverage strong cash flows to support growth and shareholder distributions.

Management Comments

• "We remain optimistic regarding the intermediate and long-term prospects of our business."
• "We believe the demand for the services we provide will continue to increase as the U.S. population ages."
• "We believe our competitive strengths... give us the ability to adapt and succeed in a healthcare industry facing regulatory uncertainty around attempts to improve outcomes and reduce costs."
• "We have been disciplined in creating a capital structure that is flexible with no significant debt maturities until 2028."
• "We continue to have a strong, well-capitalized balance sheet, including a substantial portfolio of owned real estate, and ample availability under our revolving credit facility, which along with the cash flows generated from operations should, we believe, provide sufficient support for our ability to adapt to changes in reimbursement, sustain our business model, and grow through de novo hospitals and bed additions."
• "We remain confident in the prospects of our business based on the increasing demands for the services we provide to an aging population."
• "We have a proven track record of working through difficult operating environments, and we believe in our ability to overcome current and future challenges."
• "We will continue to evaluate these laws and regulations and position the Company for this industry shift."
• "We have engaged, and will continue to engage, actively in discussions with key legislators and regulators to attempt to ensure any healthcare laws or regulations adopted or amended promote our goal of high-quality, cost-effective care and allow access to that care by patients who would benefit from treatment in inpatient rehabilitation hospitals."

Industry Context

StockSavvy.ai notes that Encompass Health operates in a highly regulated and fragmented inpatient rehabilitation industry, facing ongoing pressures from governmental and private payors to control costs. The company's focus on high-quality, cost-effective care, strategic relationships with acute-care hospitals, and investment in technology positions it well against competitors and broader industry trends towards value-based care and integrated delivery models. The aging U.S. population provides a strong demographic tailwind for long-term demand for its services, contrasting with the relatively stable number of inpatient rehabilitation facilities.

Comparison to Industry Standards

• Encompass Health was named "America's Most Awarded Leader in Inpatient Rehabilitation by Newsweek and Statista" for 2025.
• The company ranked among "Fortune's World's Most Admired Companies" and "Forbes' Most Trusted Companies in America" for 2025.
• The company's 75.9% occupancy rate in 2025 indicates efficient utilization of its facilities, which is a key operational metric in the healthcare sector.
• Encompass Health's employee engagement score of 84.2% favorable in 2025 exceeded the healthcare benchmark in all 10 categories by an average of 12.1%, suggesting strong human capital management relative to peers.
• For the year ended December 31, 2025, Encompass Health's cumulative total shareholder return (TSR) was 170.02 (from a base of 100 in 2020), compared to the S&P 500 at 196.16 and the S&P Health Care Services Select Industry Index (SPSIHP) at 113.00. This indicates strong performance relative to its industry-specific index but lagged the broader S&P 500.

Corporate Governance

Legal Proceedings

• Approximately $12 million in denied claims are awaiting review at the Administrative Law Judge (ALJ) level as of December 31, 2025.
• Approximately $21 million in denied claims are awaiting review at the Department Appeals Board (DAB) level as of December 31, 2025.
• Approximately $6 million in claims denied by the DAB are pending review by United States district courts as of December 31, 2025.
• The company is challenging the improper use of extrapolation in a 2017 Unified Program Integrity Contractor (UPIC) audit, which initially resulted in an alleged overpayment of $33.9 million (later reduced to $30.5 million, with $12.5 million overturned by an ALJ, leaving $18.0 million under appeal).
• An agreement was reached in January 2026 to settle ongoing litigation against former executive officers of the home health and hospice business, with approximately $22 million collected in February 2026.
• The company is a defendant in various lawsuits, primarily general and professional liability matters inherent in treating patients with challenging medical conditions, and labor and employment matters.

Stakeholder Impact

• Shareholders: Benefited from increased dividends and share repurchases, alongside strong financial performance. Potential risks from regulatory changes or litigation could impact future share price.
• Employees: Supported by a comprehensive total rewards program, including competitive compensation, benefits, and development opportunities. However, staffing shortages and increased labor costs remain a challenge.
• Patients: Continue to receive high-quality, cost-effective specialized rehabilitative treatment. Risks include potential limitations on access to care due to restrictive coverage determinations or audit denials.
• Joint Venture Partners: Engaged in continued strategic relationships and new joint ventures, but partners may experience operational or financial challenges that could affect joint venture hospitals.
• Creditors: The company's strong balance sheet, disciplined capital structure, and no significant debt maturities until 2028 indicate good creditworthiness and ability to service debt obligations.

Next Steps

• Continue development of new hospitals in Irmo, SC (1Q26), Concordville, PA (2Q26), Loganville, GA (2Q26), Norristown, PA (3Q26), San Antonio, TX (4Q26), Bangor, ME (4Q26), and Avondale, AZ (4Q26).
• Continue development of remote and satellite hospitals in Wesley Chapel, FL, St. George, UT, Apollo Beach, FL, Haslet, TX, Fishers, IN, and Cleveland, TN (4Q26).
• Add 150-200 new beds to existing hospitals in 2026 and 2027.
• Pay quarterly dividends in January, April, July, and October.
• Continue common stock repurchases under the remaining $332 million authorization.
• Evaluate tax and other provisions of the One Big Beautiful Bill Act (OBBBA) and their potential effects on financial position, results of operations, and cash flows.
• Engage with the Medicare Administrative Contractor (MAC) and CMS to ensure the Review Choice Demonstration (RCD) review process is consistent with existing rules, regulations, and statutes.
• Expect the HHS-OIG to issue a report on a nationwide audit of IRF claims in 2026.
• Expect to record an approximate $13 million post-tax gain from the sale of Gamma Knife Center at Barnes-Jewish Hospital, LLC, in 1Q26.
• Expect to record an approximate $16 million after-tax gain from the settlement of litigation against former executive officers of the home health and hospice business in 1Q26.
• Estimate cash income taxes of $150 million to $180 million, net of refunds, in 2026.

Key Dates

Recommendation

Encompass Health demonstrates strong operational execution and financial growth in 2025, supported by strategic expansions and favorable demographic trends. However, the company faces significant and ongoing regulatory uncertainties, particularly regarding Medicare reimbursement and audit processes, which could impact future profitability. While the long-term outlook is positive, these regulatory headwinds and increasing labor costs warrant a cautious approach. The stock has performed well relative to its industry index but lagged the broader S&P 500, suggesting it's a solid performer but with inherent industry-specific risks that prevent a 'buy' recommendation at this time.

Keywords

inpatient rehabilitation, healthcare services, Medicare, Medicaid, hospital expansion, financial performance, cybersecurity, regulatory compliance, talent management, joint ventures, shareholder return, EHC, post-acute care, financial reporting, risk management, corporate governance, executive compensation, patient outcomes